To all CLEAR III and MISTIE-ICES collaborators and guests,

You are invited to attend an open house for the CLEAR III and MISTIE‐ICES clinical trials to be held during the American Association of Neurological Surgeons (AANS) Meeting 2012 in Miami, Florida, USA.  

Monday, April 16, 2012 beginning at 5:30pm

Surfcomber Hotel – Miami South Beach (1/2 mile walk from the Convention Center)
1717 Collins Avenue
Miami Beach, Florida 33139
(LongBoard Room)

Refreshments will be served.

Please note that we cannot support any travel needs.


CLEAR trial goes mobile - New Android & iOS App

CLEAR III App home screen on Apple iPhoneAnnouncing our new CLEAR III clinical trial app for the Android and Apple iOS mobile platforms! Now, right on your cellphone or tablet, you can review protocol information, get contact numbers, and even have the exhibits to show a patient during an outcomes assessment. The information is downloaded to your phone upon your first visit so afterwards you do not have to be online; the app will work even if you are not connected to the Internet.

Some of the tools that are available include:

Randomization - a quick link to the VISION EDC database and a review of the randomization process, including a helpful list of the minimum requirements for adaptive randomization to function properly.

Emergency Contact Numbers - who to call and a link to dial the number or generate an email.

Continue reading

Bedside worksheets Updated - Redoux

Perfection can be an elusive goal, but one we are always pursuing here at the coordinating center. After our recent update of the bedside worksheets, someone found another obscure error. It's minor but to eliminate any potential confusion, we've corrected it anyway. A new version of the worksheets is now available for download.

Continue reading

200th Patient Enrolled in CLEAR-III

BIOS (Johns Hopkins' Brain Injury Outcomes clinical trial coordinating center) is thrilled to announce the CLEAR III consortium reached an important milestone today: enrollment in the CLEAR III trial has reached 200 patients! That means we are now 40% of the way to our goal of enrolling 500 patients by the end of 2014. At this rate, we are on target to complete enrollment six months or more ahead of schedule, something that will be a major accomplishment for this international study! What a great team of investigators and coordinators we have!!!

Congratulations to Dr. Agnieszka Ardelt (principal investigator), Cedric McKoy (coordinator), and the rest of the team at University of Chicago for enrolling patient #4200 today. As the treatment is blinded, we don't know whether this patient received tPA or the placebo, but after only 3 doses both the IIIrd and IVth ventricles are now open and his Modified Graeb score has dropped from 15 to 7, definitely an improved prognosis for this still critically-ill patient after experiencing a 30cc intracerebral hematoma that expanded into a large intraventricular hemorrhage.

We update the patient-by-patient enrollment information each week. Also, you can read the Quarterly Assessment of Performance (QAP) report, where we discuss the various metrics being followed in this trial and the tremendous performance of the approximately 70 sites participating in the CLEAR III intraventricular hemorrhage trial.

Another notable milestone: the results of the closely-related MISTIE II trial in intracerebral hematoma will be presented by Dr. Daniel Hanley at the International Stroke Conference in New Orleans on February 1st. Check the MISTIE study blog for details.


Our newest member of BIOS

Audrey Wynnum Hall
was born on 20-December at 7:47 PM. Weighing 7 pounds and 15.4 ounces, Audrey is the newest member of the BIOS staff.  Her mom (Amanda Bistran-Hall, a site manager on the CLEAR and MISTIE teams) and Dad (Matt Hall) are very proud and doing great!Audrey Hall

Continue reading
Google Visualization API Sample
Last updated: 16-Dec-2015
CLEAR-III Enrollment Graph
CLEAR 3 Enrollment Graph
Last Updated: 16-Jan-2015